These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33687895)

  • 1. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
    Sassoli C; Nistri S; Chellini F; Bani D
    Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-fibrotic actions of relaxin are mediated through AT
    Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
    FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts.
    Cáceres FT; Gaspari TA; Samuel CS; Pinar AA
    FASEB J; 2019 Dec; 33(12):14717-14733. PubMed ID: 31689135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions.
    Samuel CS; Bennett RG
    Biochem Pharmacol; 2022 Mar; 197():114884. PubMed ID: 34968489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin in hepatic fibrosis: What is known and where to head?
    Ezhilarasan D
    Biochimie; 2021 Aug; 187():144-151. PubMed ID: 34102254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
    Bani D
    Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5/Smad2/3 signaling pathway.
    Wu XP; Wang HJ; Wang YL; Shen HR; Tan YZ
    Exp Cell Res; 2018 Jan; 362(1):17-27. PubMed ID: 28987540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of relaxin on cardiac fibroblast-to-myofibroblast transition: an electrophysiological study.
    Squecco R; Sassoli C; Garella R; Chellini F; Idrizaj E; Nistri S; Formigli L; Bani D; Francini F
    Exp Physiol; 2015 Jun; 100(6):652-66. PubMed ID: 25786395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
    Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
    Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxin and fibrosis: Emerging targets, challenges, and future directions.
    Kanai AJ; Konieczko EM; Bennett RG; Samuel CS; Royce SG
    Mol Cell Endocrinol; 2019 May; 487():66-74. PubMed ID: 30772373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
    Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
    Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
    [No Abstract]   [Full Text] [Related]  

  • 12. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.
    Sassoli C; Chellini F; Pini A; Tani A; Nistri S; Nosi D; Zecchi-Orlandini S; Bani D; Formigli L
    PLoS One; 2013; 8(5):e63896. PubMed ID: 23704950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
    Grampp S; Goppelt-Struebe M
    Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic Actions of Serelaxin - New Roles for an Old Player.
    Samuel CS; Summers RJ; Hewitson TD
    Trends Pharmacol Sci; 2016 Jun; 37(6):485-497. PubMed ID: 26996448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design.
    D'Ercole A; Nistri S; Pacini L; Carotenuto A; Santoro F; Papini AM; Bathgate RAD; Bani D; Rovero P
    Front Pharmacol; 2022; 13():942178. PubMed ID: 36034864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
    Chow BSM; Kocan M; Shen M; Wang Y; Han L; Chew JY; Wang C; Bosnyak S; Mirabito-Colafella KM; Barsha G; Wigg B; Johnstone EKM; Hossain MA; Pfleger KDG; Denton KM; Widdop RE; Summers RJ; Bathgate RAD; Hewitson TD; Samuel CS
    J Am Soc Nephrol; 2019 Nov; 30(11):2191-2207. PubMed ID: 31511361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism.
    Yuan S; Guo D; Liang X; Zhang L; Zhang Q; Xie D
    Front Cell Dev Biol; 2023; 11():1131481. PubMed ID: 37123405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin.
    Somanader DVN; Zhao P; Widdop RE; Samuel CS
    Biochem Pharmacol; 2024 May; 223():116130. PubMed ID: 38490518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
    Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
    Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
    Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
    Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.